ArticleFrontiers in oncology2026
Impact of HER2 immunohistochemistry score on pathological complete response and survival in HER2-positive breast cancer treated with neoadjuvant therapy: differential outcomes by hormone receptor status.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the impact of differences in HER2 protein expression level based on immunohistochemistry (IHC) score (HER2 3+ Methods: This retrospective study analyzed the clinicopathological data of 308 breast cancer patients with pathologically confirmed HER2-positive status (HER2 3+ or HER2 2+/FISH+) who received NAT combined with targeted therapy at our hospital from January 2017 to December 2020. The primary observation indicators were pCR rate and disease-free survival (DFS). Results: The pCR rate in the HER2 3+ group (252 patients, 81.8%) was significantly higher than that in the HER2 2+/FISH+ group (56 patients, 18.2%) (52.4% Conclusion: High HER2 protein expression (IHC 3+) is a predictive factor for achieving a higher pCR rate with NAT in HER2-positive breast cancer. For HER2 2+/FISH+ patients, the benefit from the current standard dual-targeted therapy (trastuzumab + pertuzumab) is limited. For HER2 2+/FISH+ patients, the benefit from the current standard dual-targeted therapy (trastuzumab + pertuzumab) appears limited based on our data. However, due to the small sample size of this subgroup, this finding should be considered preliminary and requires validation in larger cohorts. These findings suggest limitations in current anti-HER2 therapy based on the existing HER2 classification. Future strategies should incorporate HER2 expression level and HR status to develop more precise individualized treatment plans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.